FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial AUSTIN, Texas, April 21, 2022 Direct Biologics, a… Read More »FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial
FDA Grants Direct Biologics Regenerative Medicine Advanced Therapy (RMAT) Designation for the use of ExoFlo in COVID-19 Related ARDS AUSTIN, Texas, April 12, 2022 Direct… Read More »FDA Grants Direct Biologics Regenerative Medicine Advanced Therapy (RMAT) Designation for the use of ExoFlo in COVID-19 Related ARDS
Direct Biologics Reveals Successful Outcomes from EXIT COVID-19 Phase II Clinical Trial AUSTIN, Texas, April 6, 2022 Direct Biologics, a regenerative biotechnology company with a… Read More »Direct Biologics Reveals Successful Outcomes from EXIT COVID-19 Phase II Clinical Trial
Direct Biologics is a science-based market leading innovator and certified cGMP manufacturer of regenerative biologic products.
Get updates on Direct Biologics and other Biotechnical news.
Privacy Policy | Terms and Conditions | ©2021 Direct Biologics LLC